Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description

Share Article

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit:

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description

Research has released its pharma report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar competitors, this will be offset by the emergence of novel therapies. Most notably, these include monoclonal antibodies secukinumab, ixekizumab and brodalumab, which are currently being developed by Alcon (Novartis subsidiary), Eli Lilly and Amgen, respectively.

To Buy The Copy of This Report Visit:


An introduction to psoriasis, which includes symptoms, epidemiology, etiology, pathophysiology, diagnosis and treatment
Analysis of the major systemic therapies in the current psoriasis marketed landscape
Analysis of the pipeline for psoriasis, which includes a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided.
Forecast projections for the systemic psoriasis market to 2020. Analysis is provided for the global market and each of the eight major markets. The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.
Analysis of strategic consolidations, including co-development and licensing deals, within the psoriasis indication

Reasons to Buy

Understand the current systemic psoriasis marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
Identify trends and developments within the psoriasis pipeline and consider how the future competitive environment will be impacted
Consider market opportunities and potential risks by examining the psoriasis clinical trial landscape in relation to industry averages
Observe projections for treatment usage patterns, annual therapy costs and market growth in the eight major markets and understand reasons for variance in projected patterns of growth in the eight major markets

To Get Download Full Report with TOC:

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Changes to Treatment Usage Patterns will Drive Market Growth
2.2 Biologics to Gain Prominence as Promising Novel Drugs Enter the Market

3 Introduction
3.1 Overview
3.2 Epidemiology
3.3 Etiology, Co-morbidities and Risk Factors
3.3.1 Genetics
3.3.2 Psoriatic Arthritis
3.3.3 Mental Health Disorders
3.3.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption
3.3.5 Infections
3.3.6 Köebner Phenomenon
3.3.7 Other Immune-mediated Diseases
3.4 Pathophysiology
3.5 Diagnosis
3.6 Treatment Options
3.6.1 Pharmacological Therapies
3.6.2 Non-pharmacological Therapies
3.6.3 Combination and Rotational Therapies
3.6.4 Quality of Life Assessments
3.7 Summary
3.8 GBI Research Report Guidance

4 Marketed Products
4.1 Overview
4.2 Methotrexate-based Products
4.3 Sandimmune/Neoral (cyclosporine/modified cyclosporine) –Novartis
4.4 Soriatane (acitretin) – Steifel Laboratories
4.5 Fumaderm (dimethyl fumarate and ethyl fumarate) – Biogen Idec
4.6 Humira (adalimumab) – Abbvie Inc.
4.7 Enbrel (etanercept) – Amgen Inc.
4.8 Remicade (infliximab) – Janssen Biotech
4.9 Stelara (ustekinumab) – Janssen Biotech
4.10 Marketed Products Heat Map

To Read Complete Report with TOC:

5 Pipeline
5.1 Overview
5.2 Pipeline Size and Distribution by Phase, Molecule Type and Program Type
5.3 Pipeline Distribution by Molecular Target
5.4 Clinical Trial Landscape
5.4.1 Clinical Trial Duration
5.4.2 Clinical Trial Size
5.5 Clinical trial failure rates
5.6 Primary and Secondary Endpoints
5.7 Summary of Psoriasis Clinical Trials
5.8 Promising pipeline molecules
5.8.1 Ixekizumab – Eli Lilly
5.8.2 Xeljanz (tofacitinib) – Pfizer
5.8.3 Brodalumab – Amgen
5.8.4 Apremilast – Celgene
5.8.5 Secukinumab – Alcon
5.9 Heat Map for Pipeline Products

6 Market Forecast to 2020
6.1 Overview
6.2 Global Market
6.3 North America
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Treatment
6.3.3 Market Size
6.4 Top Five EU Markets
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Treatment
6.4.3 Market Size
6.5 Japan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Treatment
6.5.3 Market Size
6.6 Drivers and Barriers for the Systemic Psoriasis Therapeutics Market
6.6.1 Drivers
6.6.2 Barriers

7 Co-development and Licensing deals
7.1 Co-development Deals
7.1.1 Abbvie Enters into Co-development Agreement with Biotest for Tregalizumab
7.1.2 Lycera Enters into Research Agreement with Merck & Co.
7.1.3 LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases
7.1.4 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab
7.2 Licensing Deals
7.2.1 Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug
7.2.2 Foamix Enters into Licensing Agreement with Dr. Reddy\'s Labs
7.2.3 Cipher Pharma Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch
7.2.4 Phenex Pharma Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program

8 Appendix

Contact Us:    
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
E: sales(at)marketresearchreports(dot)biz

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michell Thoras
Follow us on
Visit website